Thursday pre-open · U.S.-focused thematic intelligence · Paper tracking

Aman's Global Market Intelligence — 2026-09-10

RISK-OFF / EVENT RISK Three consecutive U.S. declines, 4.83% official 10-year yields, Brent above $100 and weak Asian breadth outweigh a small Dow/S&P futures bounce. PPI at 14:30 CEST and Oracle after the close make confirmation essential.

Generated 08:34:19 CEST (Europe/Rome) / data cutoff 08:34 CEST. U.S. cash and official Treasury marks are Sep. 9; futures, 10Y indication and Asia are early Sep. 10. European regular cash trading begins around 09:00 CEST, so Europe is pre-open. This 08:30 Italy report precedes the 14:30 CEST U.S. PPI/claims releases and 15:30 CEST U.S. cash open.

Executive dashboard

S&P 500 · Sep. 97,636.46−0.48%
Nasdaq Composite · Sep. 926,253.34−0.64%
Dow · Sep. 952,381.02−0.77%
Russell 2000 · Sep. 92,921.23−1.32%
VIX · Sep. 916.46+4.71%
U.S. 2Y / 10Y · official4.43% / 4.83%+4 / +3 bp d/d
Dollar index · overnight98.74−0.08%
WTI / Brent$96.10 / $101.00inflation pressure
Gold · overnight futures$4,452.80−0.18%
Nikkei / Hang Seng · live64,836 / 24,950−0.47% / −1.29%
Shanghai / Kospi · live3,937.8 / 7,035.0−0.35% / −0.24%
Europe · Sep. 9 closesDAX 25,576 · FTSE 10,670−1.66% / −1.31%
Euro Stoxx 50 · Sep. 96,311.56−1.58%; pre-open today
U.S. futures · early Thu.Dow +0.33% · S&P +0.18%Nasdaq-100 marginally lower

U.S. closes cross-check Reuters, Yahoo Markets and CNN. Official yields: Treasury CSV. Overnight futures/Asia/rates: CNBC live feed. Dollar, VIX, Russell, Europe and gold: Yahoo market board; CNN independently displayed the same U.S. index/VIX marks.

1 · Inflation

Oil plus PPI is the day’s binary

Brent settled $101.21 and WTI $96.05 Wednesday; overnight indications remained around $101/$96. August PPI and initial claims arrive at 08:30 ET. With the 10Y indicated 4.847%, a hot print can amplify duration pressure. Outcomes are unknown. CNBC · BLS

2 · Breadth

Risk-off broadened

Every S&P sector except energy fell; S&P decliners outnumbered advancers 4.1-to-1 and Russell 2000 lost 1.32%. A small futures bounce is not yet a breadth reversal. Reuters · Yahoo

3 · AI

Real capex, rising financing risk

Google announced at least €13B of Finland AI infrastructure and a 22-year nuclear power agreement, while the BIS warned that $1T-plus top-five-tech AI investment across 2025–26, concentration and opaque debt/private-credit financing merit scrutiny. Demand evidence and capital-risk evidence coexist. Google/Finland · BIS remarks

Market drivers

Macro, rates, geopolitics and rotation

  • Rates: official 2Y/10Y rose to 4.43%/4.83% on Sep. 9 from 4.39%/4.80%; CNBC showed the 10Y at 4.847% early Thursday and a 4.857% Wednesday high. The curve is a direct valuation headwind. Treasury · CNBC
  • Fed: CME FedWatch showed 60.2% implied probability of a 25 bp Sep. 16 hike versus 39.8% no-change, data timestamp 01:19 CT Sep. 10. This is futures-implied, not a forecast or decision. CME
  • Oil/geopolitics: the U.S.-Iran conflict and supply risk took Brent over $100. Energy gained 1.1% while every other S&P sector fell. Headline reversals can be violent in either direction. Reuters
  • Asia/Europe: Thursday Asia was broadly lower; European Sep. 9 cash indices fell 1%–2% and had not reopened by cutoff. Do not present yesterday’s European closes as live Thursday prices. CNBC Asia · Yahoo Europe
  • Calendar: PPI/claims today, CPI tomorrow and FOMC Sep. 15–16 create clustered macro risk. BLS · Fed

Earnings, regulation and verified unusual moves

  • VRT reversal: Vertiv fell 9.61% to $262.89 on 9.80M shares, fully invalidating yesterday’s conditional continuation below $268.83. No fresh operating release was established; price action, rates and broad de-risking are the evidence, not an invented cause. Nasdaq quote API
  • Semiconductor divergence: AMD gained 3.04% to $521.095 while NVDA lost 0.91% and AVGO 1.13%; the Philadelphia Semiconductor Index still rose 0.37%. AMD · NVDA · Reuters
  • Quantum unwind: IONQ −5.76%, RGTI −3.61% and QBTS −3.11% followed Tuesday’s catalyst spikes. This confirms poor post-news holding power, but does not prove a durable short trend. IONQ · RGTI · QBTS
  • Oracle binary: Oracle confirms FY27 Q1 results after today’s close, conference call 4:00 p.m. CT. Nasdaq lists ORCL and ADBE after hours. Oracle closed $161.63, down 0.55%. Oracle IR · Nasdaq
  • Regulation: the SEC’s Investor Advisory Committee meets today; no theme-specific enforcement catalyst was asserted. SEC

Theme dashboards

AI · selective

Demand persists; price action discriminates

  • Leader: AMD +3.04%. Laggards: VRT −9.61%, GOOGL −2.3%, AVGO −1.13%, NVDA −0.91%. QCOM gained 1.33% but remained below Tuesday’s $180.40 open.
  • Fresh infrastructure: Google’s €13B Finland plan covers three northern data centers and a 22-year agreement for up to 50% of one nuclear plant’s output. Capex is planned for 2027–28. Reuters
  • Supply chain: Reuters sources said Huawei raised indicated Ascend 950DT pricing 20%–50% versus two months earlier and Cambricon’s planned 690 by 20%–30%, tied to costly HBM under export restrictions. Companies did not comment; treat as sourced reporting, not company guidance. Reuters
  • Risks: yields, power/oil, capex financing, concentration, HBM, export controls, margins and valuation. The BIS specifically flagged lofty valuations and increasingly opaque financing. Reuters/BIS
Quantum · extreme speculation

Catalysts failed the second-day test

  • IONQ closed $38.14, below Tuesday’s $39.45 hold condition, after announcing fabricated Superion 256 chips, trapped ions and planned 2027 delivery. Technical damage outweighs unverified roadmap extrapolation today. IonQ
  • RGTI closed $15.24, below yesterday’s $15.37 bearish trigger. Its $100M CHIPS agreement funds three R&D projects but requires a minority government equity stake and milestone/appropriation execution. Rigetti
  • QBTS also fell 3.11% to $17.12; no equally material fresh primary release was established at cutoff.
  • Risks: architecture uncertainty, roadmap slips, independent-validation gaps, early revenue economics, cash burn, dilution, acquisitions and squeeze/gap risk. Avoid treating qubit counts as commercial utility.
Peptide biotech · binary

No fresh de-risking; maintain watch-only

  • ALT closed $3.35 (−0.30%). Its ~100-patient Phase 2 RECLAIM trial previously met the heavy-drinking-days endpoint: LS mean treatment effect −1.45 days/week at Week 24, p=0.0014; two-level WHO-risk reduction 64.4% vs 34.8%, OR 3.31, p=0.0049. Altimmune
  • Safety remains material: nausea 44% vs 24%, vomiting 18% vs 6%, severe AEs 12% vs 6%, and drug-related discontinuations 10% vs 0%. One hyponatremia SAE was deemed possibly related.
  • FDA End-of-Phase-2 discussion is planned but undated; results are sponsor-reported topline, not peer-reviewed replication. No specific 7–30 day peptide efficacy/FDA binary was verified.
  • LLY was flat (+0.03%); NVO fell 1.33%. Competition, pricing, manufacturing, safety, cash runway/dilution and binary clinical/regulatory outcomes remain central. LLY · NVO

Ranked ideas — conditional paper setups; fewer is better

1Conditional bullish

AMD · Advanced Micro Devices (Nasdaq)

Exchange/risk class: Nasdaq; mega-cap/high-beta semiconductor. Classification: relative-strength continuation. Applicable horizon: day and 1–4 weeks; 3–12+ months only after earnings, margins, FCF and valuation review. Direction: uncertain until confirmation.

Thesis/catalyst/evidence: AMD rose 3.04% to $521.095 while the Nasdaq fell 0.64% and SOX rose only 0.37%, extending Tuesday’s reported strength. Counterargument: one-day relative strength can reverse; 4.8%+ yields and AI-capex financing concerns compress duration.

Entry/confirmation: only a post-PPI hold above $521 and positive semiconductor breadth; avoid a gap chase. Invalidation/downside: cash close below $505 breaks the immediate continuation; below $500 raises air-pocket risk. Key risks: valuation, NVDA/custom-silicon competition, customer concentration, execution, HBM/supply, export controls, margins and gaps. Nasdaq data

Thesis Confidence 74
Risk 93
Opportunity 57
2Conditional bullish

QCOM · Qualcomm (Nasdaq)

Exchange/risk class: Nasdaq; large-cap semiconductor, customer/dilution risk. Classification: catalyst reclaim. Applicable horizon: day and 1–4 weeks; long-term only after contract economics/margins. Direction: uncertain.

Thesis/catalyst/evidence: +1.33% to $176.40 during a falling market; AWS collaboration covers multi-generation custom inference and optical connectivity to 1.6T. SEC terms previously tied warrant vesting to commercial arrangements/orders/purchases. Counterargument: it remains below Tuesday’s $180.40 open/$183.49 high; warrant dilution and customer concentration matter.

Entry/confirmation: close above $180.40; stronger above $183.49. Invalidation/downside: close below $172 weakens; below $168.74 cancels the setup. Key risks: Amazon concentration, product timing, margins, dilution, competition, export controls, rates and gaps. Qualcomm · Nasdaq data

Thesis Confidence 86
Risk 89
Opportunity 53
1Avoid / failed breakout

VRT · Vertiv (NYSE)

Exchange/risk class: NYSE; large-cap, high-beta AI power/cooling. Classification: failed continuation; avoid, not automatic short. Applicable horizon: day and 1–4 weeks; no structural 3–12+ month bear. Direction: uncertain; short losses can be unlimited.

Thesis/evidence: $262.89, −9.61%, on 9.80M shares invalidated yesterday’s $268.83 continuation floor in one session. Counterargument: no fresh adverse operating release was established; durable data-center thermal demand and an oversold rebound can squeeze bearish positions.

Entry/confirmation: avoid longs until a close back above $269; bearish only after a failed $269 reclaim and break below $260. Invalidation/downside: close above $280 cancels bearish framing; downside levels are uncertain after the gap. Key risks: violent rebound, valuation, project timing, input/energy cost, competition and macro. Borrow availability/fees unknown. Nasdaq data

Thesis Confidence 82
Risk 99
Opportunity 45
2Avoid / speculative fade

RGTI · Rigetti Computing (Nasdaq)

Exchange/risk class: Nasdaq Capital Market; small-cap, extreme quantum/dilution. Classification: failed post-news hold. Applicable horizon: day and 1–4 weeks only; no long-term short thesis. Direction: uncertain; unlimited short-loss risk.

Thesis/evidence: $15.24 (−3.61%) broke the $15.37 confirmation cited yesterday; $100M award requires equity issuance and project milestones. Counterargument: government funding directly supports scaling bottlenecks and can extend runway; technical milestones or policy support can trigger a squeeze.

Entry/confirmation: avoid; bearish only below $15 after a failed $15.81 reclaim. Invalidation/downside: close above $16.40 cancels; below $14.60 increases downside risk. Key risks: squeeze, government funding, technical success/failure, dilution, burn, liquidity and gaps. Borrow data unavailable. Rigetti · price

Thesis Confidence 89
Risk 100
Opportunity 41

Watchlist — four conditional setups, not recommendations

Earnings binary

ORCL · Oracle (NYSE)

Risk class: mega-cap cloud; capex/debt/customer concentration. Classification/horizon: event watch; day/1–4 weeks, long-term after FCF/debt review. Direction: uncertain.

Thesis/catalyst: FY27 Q1 tonight; prior FY26 Q4 cloud revenue was $9.9B (+47%) and IaaS $5.8B (+93%). Counter: FY26 year-end non-current borrowings were $122.3B and PP&E $100.0B, making financing and conversion critical. Confirmation: post-earnings close above $165 with improving RPO/cloud/FCF quality. Invalidation/downside: below $160, then an earnings gap can bypass levels. Risks: capex, debt, OpenAI/customer exposure, capacity, margins and guidance. Oracle financials · price

Confidence 90
Risk 98
Opportunity 50
Highly speculative

IONQ · IonQ (NYSE)

Risk class: quantum/acquisition, extreme duration. Classification/horizon: broken post-Investor-Day range; day/1–4 weeks; 3–12+ months only after independent system/unit-economic proof. Direction: uncertain.

Evidence: $38.14 (−5.76%) broke $39.45; planned 2027 delivery means commercialization proof is prospective. Counter: fabricated chips and trapped ions are tangible development milestones. Confirmation: regain $40.47, then $44.43. Invalidation/downside: below $38 exposes $36.78 and lower. Risks: integration, burn, dilution, roadmap, technical validation, liquidity and gaps. IonQ · price

Confidence 88
Risk 100
Opportunity 34
Small-cap / sub-$5 biotech

ALT · Altimmune (Nasdaq)

Risk class: small-cap peptide biotech; penny-price/binary/financing. Classification/horizon: clinical-platform watch; 1–4 weeks only on technical confirmation; 3–12+ months after FDA alignment and runway review. Direction: uncertain.

Evidence: RECLAIM met endpoints with disclosed p-values; $3.35 remains unresponsive and no dated near-term binary was verified. Counter: GI AEs, severe AEs and 10% related discontinuations complicate Phase 3; sponsor topline may not replicate. Confirmation: close above $3.55. Invalidation/downside: below $3.25, then $3.10. Risks: endpoint, safety, FDA path, cash runway/dilution, manufacturing, competition and gaps. trial data · price

Confidence 72
Risk 100
Opportunity 31
AI capex / power

GOOGL · Alphabet (Nasdaq)

Risk class: mega-cap platform; capex/regulatory/AI-return risk. Classification/horizon: capex digestion watch; 1–4 weeks and 3–12+ months after FCF/returns review. Direction: uncertain.

Thesis/catalyst: Finland plan offers capacity, cold-climate cooling and contracted nuclear power. Counter: shares fell 2.3%; Alphabet’s stated 2026 global investment of $195B–$205B elevates execution and return-on-capital risk. Confirmation: relative strength versus Nasdaq after PPI and a close above the Sep. 9 high (live chart required). Invalidation/downside: new weekly low with rising yields; no fabricated static price level. Risks: regulation, monetization, power, construction, financing, competition and valuation. Reuters

Confidence 82
Risk 78
Opportunity 46

Scores are 0–100. Higher Risk means riskier. Thesis Confidence measures evidence quality, never probability of profit. All entries are conditional; no fill is assumed and gaps can bypass invalidations.

Changes versus the 2026-09-09 report

  • Risk-off deepened: the S&P, Nasdaq and Dow fell for a third session; Russell underperformed and breadth was 4.1-to-1 negative.
  • Oil/rates worsened: Brent moved from yesterday’s $99.44 early indication to a $101.21 settlement; official 2Y/10Y rose to 4.43%/4.83%. This keeps the regime risk-off despite mildly positive Dow/S&P futures.
  • VRT was invalidated: −9.61% to $262.89 broke both the $280.53 weakness line and $268.83 invalidation. It moves from #1 bullish to avoid/failed breakout.
  • AMD replaces VRT at #1 conditional bullish: +3.04% relative strength versus falling broad indexes. This is technical selection, not a new company catalyst.
  • QCOM improved but did not confirm: +1.33% to $176.40, still below $180.40/$183.49 reclaim levels.
  • Quantum weakened: IONQ broke $39.45 and RGTI broke $15.37; Tuesday’s heavy-volume fades became outright second-day losses. RGTI remains avoid; IONQ stays watch-only.
  • Fresh AI evidence is two-sided: Google’s large power-backed buildout supports infrastructure demand, while the BIS warning and HBM price squeeze raise financing/supply-chain risk.
  • Peptide view unchanged: ALT remains watch-only; no fresh trial, FDA decision or dated 7–30 day binary was established.

Important catalysts: next 7–30 days

Sep. 10 · 14:30 CEST — U.S. August PPI + weekly claims
First inflation test after oil’s surge; 08:30 Italy report necessarily precedes it. Outcome unknown. BLS · CNBC
Sep. 10 · after U.S. close — ORCL and ADBE earnings
Cloud backlog/consumption, AI capex, financing, margins and FCF. Nasdaq · Oracle
Sep. 11 · 14:30 CEST — U.S. August CPI / real earnings
Key duration and Fed-pricing catalyst. BLS schedule
Sep. 15–16 — FOMC and projections
CME implied 60.2% hike odds at cutoff; policy decision Sep. 16 is authoritative. Fed · CME
Sep. 18 — U.S. industrial production
09:15 ET; relevant to cyclical, power and data-center supply chains. Fed calendar
Sep. 21 — Broadcom company event marker
Treat as information checkpoint, not assumed earnings. Broadcom IR
Sep. 29 / 30 — IONQ warrants cease trading / expire
Capital-structure flows may distort price; common stock remains listed. SEC 8-K
Peptide checkpoint — undated
ALT plans an FDA End-of-Phase-2 discussion, but no specific date or 7–30 day efficacy/FDA binary was verified. Do not trade an invented calendar. Altimmune

Bottom line by horizon

Day trade · today

Bias: defensive and post-PPI confirmation-only. AMD above $521 and QCOM above $180.40 are the only conditional longs; avoid pre-event VRT/quantum gap trades.

Biggest risk: PPI plus geopolitical/oil whipsaw. Regime invalidation: Brent retreats below $100, 10Y below 4.80% and S&P reclaims 7,673 with positive breadth.

1–4 week swing

Bias: reduced size through CPI/FOMC; favor confirmed semiconductor relative strength over speculative quantum or sub-$5 biotech.

Biggest risk: sustained oil shock/hot inflation forces a hike and higher term premium. Invalidation: S&P closes above 7,748 with 10Y below 4.70% and broader participation.

3–12+ month investment

Bias: AI demand is tangible, but financing, return on capex, power and margins must be underwritten. Quantum needs independent utility/unit economics; peptide needs Phase 3/regulatory/cash proof.

Biggest risk: capex debt cycle, concentration, dilution or technical/clinical failure. Invalidation: durable deterioration in orders, margins and FCF—not one volatile day—breaks the structural AI case.

Data quality, retrievals and limitations

  • Live research exceeded the minimum: separate retrievals covered CNBC’s live market feed, Reuters market wrap, Reuters AI/Google/HBM reports, Yahoo/CNN market boards, Nasdaq quote and earnings APIs, Treasury CSV, CME FedWatch, Fed/BLS/SEC calendars, Oracle/Qualcomm/Rigetti/IonQ/Altimmune primary releases and ClinicalTrials.gov.
  • Cross-checks: U.S. large-index closes matched Reuters and Yahoo/CNN within minor vendor rounding; Treasury’s Sep. 9 CSV supplied 2Y/10Y and CNBC independently showed the 10Y range; Oracle’s date matched Oracle IR and Nasdaq; quantum and peptide details use issuer releases and prior SEC links.
  • Timestamps: U.S./theme prices are Sep. 9 non-real-time closes from Nasdaq at cutoff. CNBC’s futures/Asia/rates were posted roughly 2–5 hours before cutoff. CME probability timestamp was 01:19:34 CT Sep. 10. Premarket and futures can reverse.
  • Primary-source distinction: Google/Finland and Chinese HBM pricing details are Reuters reporting; the latter relies on unnamed sources and companies declined comment. BIS comments are attributed. Issuer roadmap and trial statements are company claims, not independent proof.
  • Quote-source retries: Yahoo chart API returned HTTP 429 for all requested symbols; Stooq quote URLs returned HTTP 404; Nasdaq historical endpoint returned empty rows. Nasdaq’s quote-info API succeeded for theme closes, while Reuters/CNBC/Yahoo/CNN supplied indexes. Because three independent historical/intraday routes did not yield reliable OHLC, no fresh intraday highs/lows or volume averages are invented.
  • European timing: Europe had not opened by the 08:34 cutoff. Sep. 9 closes are explicitly labeled; no live Thursday European print is claimed.
  • Commodity precision: CNBC supplied verified Wednesday settlements and early market indications; Yahoo/CNN supplied the overnight board. Quotes may differ slightly by contract/refresh time.
  • Biotech discipline: RECLAIM is Phase 2 sponsor-reported topline with disclosed endpoints/statistics/safety; FDA alignment, peer review, Phase 3 replication and current cash runway remain unresolved. No new peptide catalyst was manufactured.
  • Research discipline: no analyst target/rating, forward valuation multiple, borrow availability/fee, unreleased result or guaranteed contract value is invented. Short losses can be unlimited.
Risk notice: Initial two weeks are paper-tracking. Research only, not guaranteed, personalized, fiduciary, legal or tax advice. Verify live quotes, liquidity and primary filings before any action.